Literature DB >> 28487124

Concordance the hemoglobin glycation index with glycation gap using glycated albumin in patients with type 2 diabetes.

Mee Kyoung Kim1, Jee Sun Jeong1, Hyuk-Sang Kwon1, Ki Hyun Baek1, Ki-Ho Song2.   

Abstract

BACKGROUND: The hemoglobin glycation index (HGI) is an index of differences in the glycation of hemoglobin according to blood glucose level. The glycation gap (G-gap) is an empiric measure of the extent of disagreement between hemoglobin A1C (HbA1C) and glycated albumin (GA). The aim of this study was to investigate the extent of agreement between the HGI and G-gap with respect to GA level, and to elucidate factors related to a high HGI.
METHOD: Data were obtained from 105 patients with type 2 diabetes, and fasting blood glucose (FBG), HbA1c, and GA values were measured simultaneously. The G-gap was calculated as the difference between the measured and GA-based predicted HbA1c levels. HGI was calculated as the difference between measured and FBG-based predicted HbA1c levels.
RESULTS: The HGI and G-gap were highly correlated according GA (r=0.722, P<0.001). In general, the two indices were similar in terms of both direction and magnitude. The classification of patients as high, moderate, or low glycators based on HGI versus G-gap was consistent for the majority of the population and only 5% of patients were reclassified from high to low or low to high. Fasting C-peptide levels decreased linearly, and the percentage of patients using insulin increased linearly, between the lowest and highest HGI tertile (both P<0.05).
CONCLUSIONS: There was 95% agreement between the HGI and G-gap using GA among type 2 diabetes patients. Furthermore, a high HGI was associated with a higher prevalence of insulin use among type 2 diabetes patients.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fructosamine; Glycated albumin; Glycation gap; Hemoglobin glycation index; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2017        PMID: 28487124     DOI: 10.1016/j.jdiacomp.2017.04.015

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  7 in total

1.  Implications of the Hemoglobin Glycation Index on the Diagnosis of Prediabetes and Diabetes.

Authors:  Daniel S Hsia; Neda Rasouli; Anastassios G Pittas; Christine W Lary; Anne Peters; Michael R Lewis; Sangeeta R Kashyap; Karen C Johnson; Erin S LeBlanc; Lawrence S Phillips; James M Hempe; Cyrus V Desouza
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

Review 2.  Effects of Propolis Extract and Propolis-Derived Compounds on Obesity and Diabetes: Knowledge from Cellular and Animal Models.

Authors:  Hiroshi Kitamura
Journal:  Molecules       Date:  2019-12-01       Impact factor: 4.411

3.  Genome-wide meta-analysis in Japanese populations identifies novel variants at the TMC6-TMC8 and SIX3-SIX2 loci associated with HbA1c.

Authors:  Tsuyoshi Hachiya; Shohei Komaki; Yutaka Hasegawa; Hideki Ohmomo; Kozo Tanno; Atsushi Hozawa; Gen Tamiya; Masayuki Yamamoto; Kuniaki Ogasawara; Motoyuki Nakamura; Jiro Hitomi; Yasushi Ishigaki; Makoto Sasaki; Atsushi Shimizu
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379

4.  Consistency of the Glycation Gap with the Hemoglobin Glycation Index Derived from a Continuous Glucose Monitoring System.

Authors:  Han Na Joung; Hyuk-Sang Kwon; Ki-Hyun Baek; Ki-Ho Song; Mee Kyoung Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

5.  Standardizing the haemoglobin glycation index.

Authors:  James M Hempe; Shengping Yang; Shuqian Liu; Daniel S Hsia
Journal:  Endocrinol Diabetes Metab       Date:  2021-09-23

6.  Heterogeneous treatment effects of intensive glycemic control on major adverse cardiovascular events in the ACCORD and VADT trials: a machine-learning analysis.

Authors:  Justin A Edward; Kevin Josey; Gideon Bahn; Liron Caplan; Jane E B Reusch; Peter Reaven; Debashis Ghosh; Sridharan Raghavan
Journal:  Cardiovasc Diabetol       Date:  2022-04-27       Impact factor: 8.949

7.  Generalizability of heterogeneous treatment effects based on causal forests applied to two randomized clinical trials of intensive glycemic control.

Authors:  Sridharan Raghavan; Kevin Josey; Gideon Bahn; Domenic Reda; Sanjay Basu; Seth A Berkowitz; Nicholas Emanuele; Peter Reaven; Debashis Ghosh
Journal:  Ann Epidemiol       Date:  2021-07-17       Impact factor: 3.797

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.